Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

586 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.
Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD. Taher AT, et al. Among authors: cappellini md. Eur J Haematol. 2014 Jun;92(6):521-6. doi: 10.1111/ejh.12270. Epub 2014 Mar 25. Eur J Haematol. 2014. PMID: 24460655 Free PMC article. Clinical Trial.
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients.
Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhang Y, Cappellini MD. Taher AT, et al. Among authors: cappellini md. Am J Hematol. 2013 Jun;88(6):503-6. doi: 10.1002/ajh.23445. Epub 2013 May 13. Am J Hematol. 2013. PMID: 23553596 Free PMC article. Clinical Trial.
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.
Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhu Z, Cappellini MD. Taher AT, et al. Among authors: cappellini md. Ann Hematol. 2013 Nov;92(11):1485-93. doi: 10.1007/s00277-013-1808-z. Epub 2013 Jun 18. Ann Hematol. 2013. PMID: 23775581 Free PMC article. Clinical Trial.
Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.
Taher AT, Cappellini MD, Aydinok Y, Porter JB, Karakas Z, Viprakasit V, Siritanaratkul N, Kattamis A, Wang C, Zhu Z, Joaquin V, Uwamahoro MJ, Lai YR. Taher AT, et al. Among authors: cappellini md. Blood Cells Mol Dis. 2016 Mar;57:23-9. doi: 10.1016/j.bcmd.2015.11.002. Epub 2015 Nov 11. Blood Cells Mol Dis. 2016. PMID: 26852651 Free article. Clinical Trial.
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes.
Taher AT, Porter JB, Kattamis A, Viprakasit V, Cappellini MD. Taher AT, et al. Among authors: cappellini md. Drug Des Devel Ther. 2016 Dec 15;10:4073-4078. doi: 10.2147/DDDT.S117080. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 28008230 Free PMC article. No abstract available.
586 results